

Resource Summary Report

Generated by ASWG on Aug 9, 2026

CD28 Monoclonal Antibody (CD28.2), Functional Grade, eBioscience

RRID:AB_468926

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# 16-0289-81, RRID:AB_468926)

Antibody Information

URL: http://antibodyregistry.org/AB_468926

Proper Citation: (Thermo Fisher Scientific Cat# 16-0289-81, RRID:AB_468926)

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow, Functional
Consolidation on 1/2020: AB_468926, AB_10114301

Antibody Name: CD28 Monoclonal Antibody (CD28.2), Functional Grade, eBioscience

Description: This monoclonal targets CD28

Target Organism: human

Clone ID: Clone CD28.2

Antibody ID: AB_468926

Vendor: Thermo Fisher Scientific

Catalog Number: 16-0289-81

Record Creation Time: 20251216T074250+0000

Record Last Update: 20260225T231713+0000

Ratings and Alerts

No rating or validation information has been found for CD28 Monoclonal Antibody (CD28.2), Functional Grade, eBioscience.

No alerts have been found for CD28 Monoclonal Antibody (CD28.2), Functional Grade, eBioscience.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

de Blas A, et al. (2026) Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity. Cancer research, 86(12), 2896.

Wang Z, et al. (2026) Genome-Wide CRISPR Screen Identifies a microRNA Orchestrating Pleiotropic Resistance to Targeted Therapy and T Cell Immunity in Melanoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e15158.

Andraos E, et al. (2026) CircRNAs derived from the tyrosine phosphatase PTPN22 impact chemosensitivity in ALK-positive T-cell lymphomas. Scientific reports.

Roostaei T, et al. (2026) Cell-type- and state-resolved transcriptomics uncovers distinct T cell and monocyte dysregulation in multiple sclerosis. Cell reports, 45(6), 117417.

Orta Resendiz A, et al. (2026) Expansion of NKG2A+CD8+ T cells with regulatory signatures distinguish individuals living with HIV-2 from those with HIV-1. Med (New York, N.Y.), 7(6), 101143.

Zhu L, et al. (2026) A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer. Cancer discovery, 16(7), 1360.

Yoshichika R, et al. (2026) Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancer. Cancer immunology, immunotherapy : CII, 75(4).

Hesterberg RS, et al. (2025) Lymphoma accelerates T cell and tissue aging. Cancer cell.

Drózd M, et al. (2025) Immediate early splicing controls translation in activated T-cells and is mediated by hnRNPC2 phosphorylation. The EMBO journal, 44(6), 1692.

Lou J, et al. (2025) Step-Wise Assembly of LAT Signaling Clusters Immediately After T Cell Receptor Triggering Contributes to Signal Propagation. International journal of molecular sciences, 26(9).

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. *Cell*.

Cerveró-Varona A, et al. (2025) Amniotic epithelial Cell microvesicles uptake inhibits PBMCs and Jurkat cells activation by inducing mitochondria-dependent apoptosis. *iScience*, 28(2), 111830.

Krawczyk M, et al. (2025) The costimulatory domain influences CD19 CAR-T cell resistance development in B-cell malignancies. *bioRxiv : the preprint server for biology*.

Honnayakanahalli Marichannegowda M, et al. (2025) Genetic signatures in the highly virulent subtype B human immunodeficiency virus-1 conferring resistance to broadly neutralizing antibodies. *iScience*, 28(7), 112847.

Revilla SA, et al. (2025) Impact of 3D cell culture hydrogels derived from basement membrane extracts or nanofibrillar cellulose on CAR-T cell activation. *iScience*, 28(9), 113234.

Chi H, et al. (2025) SEMA3G-NRP1 Signaling Functions as an Immune Checkpoint That Enables Tumor Immune Evasion by Impairing T-cell Cytotoxicity. *Cancer research*, 85(5), 912.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. *Cancer cell*, 43(8), 1512.

Mocholi E, et al. (2025) Glycolytic reprogramming shapes the histone acetylation profile of activated CD4⁺ T cells in juvenile idiopathic arthritis. *Cell reports*, 44(2), 115287.

Wang L, et al. (2024) Induction of immortal-like and functional CAR T cells by defined factors. *The Journal of experimental medicine*, 221(5).

Shen C, et al. (2024) The rebalancing of the immune system at the maternal-fetal interface ameliorates autism-like behavior in adult offspring. *Cell reports*, 43(10), 114787.